Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 18/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4458364 | 0.95 | MET (0.53) | METFLT3AXL | |
| SCHEMBL3830213 | 0.91 | MET (0.47) | MET | |
| SCHEMBL3830873 | 0.91 | EGFR (0.49) | MET | |
| SCHEMBL3829110 | 0.90 | MET (0.47) | METFLT3 | |
| SCHEMBL2328218 | 0.89 | MET (0.54) | METFLT3 | |
| SCHEMBL2200943 | 0.89 | MET (0.53) | MET | |
| SCHEMBL2330029 | 0.88 | MET (0.56) | METFLT3AXL | |
| SCHEMBL9987663 | 0.88 | MET (0.56) | METFLT3AXL | |
| SCHEMBL3858219 | 0.88 | MET (0.55) | METFLT3 | |
| SCHEMBL374347 | 0.87 | MET (0.55) | METFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-8497284-B2 | C-met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120022065-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022065-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | MET 2/4885FLT3 7/4885AXL 241/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MET 3/4885FLT3 7/4885AXL 109/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | MET 3/4885FLT3 7/4885AXL 109/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | MET 3/4885FLT3 7/4885AXL 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.